Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:22:02.730Z.
Calculation as of: 2026-10-06T22:22:02.730Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0d034b685c23fadaea9476ccc197406393d04780d3c67e2351ab6b6412cf62fb
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fractyl Health, Inc. (GUTS) | $60.42M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A | 110.41 | 110.41 | 110.41 |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A | N/A | N/A | N/A |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | N/A | 2.96 | 2.96 | 2.96 |
| InterCure Ltd. (INCR)vs › | $63.02M | N/A | 14.25 | 33.42 | 30.04 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.57
Forward EPS (Est.)
$-0.34
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
